Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

About this update from Jupiter Neurosciences, Inc.

[{"type":"text","content":"JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.","length":345,"tagName":"p"},{"type":"text","content":"Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.","length":238,"tagName":"p"},{"type":"text","content":"Event Details:","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Conference: 3rd Annual DealFlow Discovery Conference","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"Venue: The Borgata Hotel, Casino & Spa","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: Atlantic City, NJ","length":27,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: January 28-29, 2026","length":25,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":146,"olType":false},{"type":"text","content":"Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).","length":169,"tagName":"p"},{"type":"text","content":"About Jupiter Neurosciences, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications ...

More updates from Jupiter Neurosciences, Inc.